Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Pentobarbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | MMP9 | P14780 | 4/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentobarbital SCHEMBL2376470 | 1.00 | CYP3A4 (1.00) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL735353 | 1.00 | CYP3A4 (1.00) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL26057 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL4207760 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL7639355 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL1256614 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL3695587 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL26056 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL3245534 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL30173355 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 50772 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719552-A1 | INDUCTION OF GENERAL ANESTHESIA IN ADULTS UNDERGOING ELECTIVE SURGERY | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| CN-118633570-B | Construction method and application of mouse liver injury model by radiotherapy and immunotherapy | 复旦大学附属中山医院 | 2026-02-27 | — | — | CN | claimed |
| US-20260048042-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | NEUROCRINE BIOSCIENCES INC (US) | 2026-02-19 | — | — | US | claimed |
| US-20260041939-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION VIA TRANSCRANIAL-FOCUSED-ULTRASOUND | SUNNYBROOK RES INST (CA) | 2026-02-12 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| WO-2025245294-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245292-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT LOSS | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-RE32393-E | STABLE, OIL IN WATER EMULSION | KABIVITRUM AB (SE) | 1987-04-07 | — | — | US | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| US-4244939-A | RADIOIMMUNOASSAY | BAXTER TRAVENOL LABORATORIES, INC. (US) | 1981-01-13 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
| US-4168308-A | Composition for enhancing the administration of pharmacologically active agents | APOTEKSVARUCENTRALEN VITRUM AB (SE) | 1979-09-18 | — | — | US | claimed |
| US-4151268-A | ASSAYING FOR 5-SUBSTITUTED-1,3-UNSUBSTITUTED BARBITURIC ACIDS BY COMPLEXING WITH GAMMA GLOBULIN FRACTION PROTEINS | HOFFMANN-LA ROCHE INC. (US) | 1979-04-24 | — | — | US | claimed |
| US-RE29875-E | THEOPHYLLINE SOLUBILIZED BY GLYCERYL GUAIACOLATE, POTASSIUM GUAIACOL SULFONATE OR GUAIACOL | MEAD JOHNSON & COMPANY (US) | 1979-01-02 | — | — | US | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
| US-4107153-A | Heat-resistant thermosetting polyimide resin | TOSHIBA CHEMICAL PRODUCTS CO., LTD. (JP) | 1978-08-15 | — | — | US | claimed |
| US-4097545-A | Heat-resistant thermosetting polyimide resin with bis-phenol-epichlorohydrin reaction product | TOSHIBA CHEMICAL PRODUCTS CO. LTD. (JA) | 1978-06-27 | — | — | US | claimed |